selected publications view all publications via PubMed Roumiantsev S, de Aos I, Varticovski L, Ilaria RL, Van Etten RA. The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice, but not for lymphoid leukemogenesis or for activation of phosphatidylinositol 3-kinase. Blood 2001; 97:4-13. [ view publication ] Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA. Interleukin-3 and granuolcyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease by BCR/ABL. Blood 2001; 97:1442-1450. [ view publication ] Smith KM, Van Etten RA. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J. Biol. Chem. 2001; 276:24372-24379. [ view publication ] Brasher BB, Roumiantsev S, Van Etten RA. Mutagenic analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene 2001; 20:7744-7752. [ view publication ] Li S, Couvillon AD, Brasher BB, Van Etten RA. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 2001; 20:6793-6804. [ view publication ] Million RP, Aster J, Gilliland DG, Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 2002; 99:4568-4577. [ view publication ] Van Etten RA. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene 2002; 21:8643-8651. [ view publication ] Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in CML by mutation of Tyr253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 2002; 99:10700-10705. [ view publication ] Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003; 424:561-565. [ view publication ] Van Etten RA. c-Abl regulation: A tail of two lipids. Curr. Biol. 2003; 13:R608-610. [ view publication ] Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol. Cell 2003; 12:27-37. [ view publication ] Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NCP, Van Etten RA. Distinct stem cell myeloproliferative/T-lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes of 8p11 translocations. Cancer Cell 2004; 5:287-298. [ view publication ] Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol. Cell. Biol. 2004; 24:4685-4695. [ view publication ] Van Etten RA, Shannon KM. Focus on myeloproliferative disease and myelodysplastic syndromes. Cancer Cell 2004; 6:547-552. [ view publication ] Krause DS, Van Etten RA. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood 2004; 104:4236-4244. [ view publication ] Return to Top Please send feedback to the MORI Administrator © 2002-2012, Molecular Oncology Research Institute, All Rights Reserved